Kairasec

Candesartan Cilexetil, the active ingredient in Kairasec, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is prescribed to manage high blood pressure and to support treatment of heart failure in adult patients. GNH USA supplies Kairasec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kairasec, an angiotensin II receptor blocker, is used in conditions where inhibition of the renin‑angiotensin system improves cardiovascular outcomes.

Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and myocardial infarction. Heart failure: improves ventricular function and decreases hospitalisation rates in patients with reduced ejection fraction.

Candesartan Cilexetil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache. - Fatigue. - Nasal congestion. - Upper respiratory tract infection. - Diarrhoea.

Serious or Rare Side Effects: - Severe hypotension, particularly in volume‑depleted patients. - Hyperkalaemia. - Acute kidney injury or worsening renal function. - Angio‑oedema. - Hepatic enzyme elevations. - Myocardial infarction (rare).

Before initiating therapy, clinicians should assess renal function, electrolyte balance, and concomitant medications.

Monitor blood pressure: adjust dose if hypotension occurs. Check renal function: avoid use in patients with severe renal impairment. Assess potassium levels: avoid in hyperkalaemia. Avoid in pregnancy: teratogenic risk is not established. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Candesartan Cilexetil can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients. - Potassium‑sparing diuretics or supplements leading to hyperkalaemia. - Dual blockade with ACE inhibitors or other ARBs.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may reduce antihypertensive effect. - Lithium: increased risk of toxicity. - Rifampin: may lower candesartan plasma concentrations.